| Sports Therapy And Rehabilitation Inc. | |
|
303 Fleischmann Wy, Carson City, NV 89703 | |
| (775) 885-7827 | |
| (775) 885-2301 |
| Full Name | Sports Therapy And Rehabilitation Inc. |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 303 Fleischmann Wy, Carson City, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114027000 | NPI | - | NPPES |
| 003416133 | Medicaid | NV | |
| 100505561 | Medicaid | NV |
| Provider Name | Luann M Tucker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1700986700 PECOS PAC ID: 2163550260 Enrollment ID: I20101023000133 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
| Provider Name | Linda L Wear |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1790885705 PECOS PAC ID: 2567638398 Enrollment ID: I20111229000134 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
| Provider Name | Michele E Munson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396956876 PECOS PAC ID: 2860671690 Enrollment ID: I20120403000067 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
| Provider Name | Michael A Bernhard |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871582411 PECOS PAC ID: 1557516960 Enrollment ID: I20130308000186 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
| Provider Name | Ricardo Ugarte |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992572192 PECOS PAC ID: 6709237001 Enrollment ID: I20240111001692 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sports Therapy And Rehabilitation Inc. 303 Fleischmann Wy, Carson City, NV 89703 Ph: (775) 885-7827 | Sports Therapy And Rehabilitation Inc. 303 Fleischmann Wy, Carson City, NV 89703 Ph: (775) 885-7827 |
News Archive
An international group led by Dr Banafshe Larijani, an Ikerbasque researcher seconded to the Biofisika Institute (UPV/EHU-University of the Basque Country, CSIC), has developed a new diagnostic method making it possible to accurately predict which cancer patients will respond positively to immunotherapy.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
By following a few basic rules for handling central venous catheters, nurses and doctors at a group of children's hospitals have, in three years, prevented nearly a thousand infections and saved more than a hundred children's lives and millions of dollars, according to a study by investigators at Johns Hopkins Children's Center and elsewhere.
› Verified 1 days ago
Ms. Corinne Marie Holmes, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 680 W Nye Ln Ste 205, Carson City, NV 89703 Phone: 775-882-2211 Fax: 775-882-2212 | |
Gisel David, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1749 N Stewart St Ste 50, Carson City, NV 89706 Phone: 775-348-8800 Fax: 833-687-1419 | |
High Desert Therapists, Inc. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2874 N Carson St, Suite 100, Carson City, NV 89706 Phone: 775-883-4161 | |
Stacy L Carman, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 931 Mica Dr Ste 1, Carson City, NV 89705 Phone: 775-267-3396 Fax: 775-267-3398 | |
Deborah A. Beaty, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 235 Sarah Dr, Carson City, NV 89706 Phone: 775-247-8231 | |
Mr. Taylor Daniel Blattenberger, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1749 N Stewart St Ste 50, Carson City, NV 89706 Phone: 775-392-3689 Fax: 775-783-6191 |